Trials / Recruiting
RecruitingNCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Cybrexa Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBX-12 | CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety. |
Timeline
- Start date
- 2024-09-25
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2024-03-18
- Last updated
- 2025-10-06
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06315491. Inclusion in this directory is not an endorsement.